Enhertu (Trastuzumab Deruxtecan) is the Preferred Treatment Over Tukysa in Second-Line HER2-Positive Metastatic Breast Cancer
Trastuzumab deruxtecan (Enhertu) is the preferred second-line therapy following progression on trastuzumab, pertuzumab, and taxane, with the highest level of evidence (ESMO-MCBS 1A). 1 Tucatinib (Tukysa) combined with trastuzumab and capecitabine is reserved for third-line therapy or later, after patients have received at least two prior anti-HER2 regimens. 1
Treatment Sequencing Algorithm
Second-Line Setting (After Trastuzumab + Pertuzumab + Taxane)
- Standard choice: Trastuzumab deruxtecan (T-DXd) 1
- Alternative if T-DXd unavailable or unsuitable: T-DM1 (e.g., patients with pre-existing interstitial lung disease) 1
- Exception for brain metastases: Consider tucatinib + trastuzumab + capecitabine in patients with active brain metastases without symptomatic mass effect 2
Third-Line Setting (After T-DXd)
- Preferred choice: Tucatinib + trastuzumab + capecitabine 1
- Multiple national guidelines (Austria, Canada, France, Italy, Germany) specifically recommend the tucatinib combination following second-line T-DXd 1
- Real-world data demonstrates median OS of 13-14 months with tucatinib after T-DXd 1
- Expert consensus (98% of 80 Italian/Spanish oncologists) supports the sequence: trastuzumab/pertuzumab → T-DXd → tucatinib combination 1
Evidence Quality and Strength
The recommendation for T-DXd in second-line is based on the DESTINY-Breast03 trial, which demonstrated superior outcomes compared to T-DM1 1. This represents the highest quality evidence (ESMO-MCBS 1A) from 2025 guidelines.
For tucatinib, the HER2CLIMB trial established its efficacy in heavily pretreated patients (median of 6 prior treatments) who had received trastuzumab, pertuzumab, and T-DM1 3. The FDA approval specifically states tucatinib is indicated "who have received one or more prior anti-HER2-based regimens in the metastatic setting" 4, but clinical practice and guidelines position it after T-DXd.
Special Consideration: Brain Metastases
For patients with active brain metastases, the treatment algorithm differs:
- Tucatinib + trastuzumab + capecitabine may be offered in second-line for patients with brain metastases without symptomatic mass effect 2
- The HER2CLIMB trial demonstrated CNS progression-free survival at 1 year of 24.9% vs 0% (placebo), with median CNS-PFS of 7.6 months 3
- CNS objective response rate in active brain metastases was 47.3% with tucatinib vs 20.0% with placebo 1
- Local therapy (surgery, stereotactic radiotherapy) should still be considered first when feasible 1
Key Clinical Pitfalls
Interstitial lung disease (ILD) with T-DXd: Monitor carefully for pulmonary symptoms. ILD occurred in 13.6% of patients in DESTINY-Breast01, including 2.2% grade 5 events 5. This is the primary reason to consider tucatinib earlier or use T-DM1 instead.
Hepatotoxicity with tucatinib: Grade ≥3 ALT/AST elevations occur in approximately 16.5% of patients 1. Monitor liver enzymes every 3 weeks and manage with dose reductions 4, 6.
Diarrhea with tucatinib combination: Most common adverse event, manageable with antidiarrheals and dose modifications 3, 6, 7. Grade 3-4 diarrhea requires aggressive supportive care.
Real-World Performance After T-DXd
Recent real-world data specifically examining tucatinib after T-DXd shows 8:
- Median PFS: 4.7 months (95% CI 3.9-5.6)
- Median OS: 13.4 months (95% CI 11.1-NR)
- Objective response rate: 32.6%
- Patients with active brain metastases: median PFS 4.7 months, median OS 12.4 months
These outcomes demonstrate clinically meaningful benefit even in this heavily pretreated population (median 4 prior lines) 8, 9.